An Active Surveillance to Monitor the Real World Safety in Indian Patients Prescribed Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis
Phase of Trial: Phase IV
Latest Information Update: 02 May 2019
Price : $35 *
At a glance
- Drugs Nintedanib (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 30 Apr 2019 Planned End Date changed from 31 Dec 2019 to 31 Dec 2021.
- 30 Apr 2019 Planned primary completion date changed from 31 Dec 2019 to 31 Dec 2021.
- 04 Mar 2019 Planned number of patients changed from 200 to 400.